Shire plc the global specialty biopharmaceutical company, announces results for the three months to March 31, 2010. Women who have gestational glucose intolerance (a condition less severe than gestational diabetes) exhibit multiple cardiovascular risk factors as early as three months after birth, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009. DUBLIN, October 30 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009. Q3 2009 Financial Highlights Q3 2009(1) Product sales $603 million -15% Product sales from core products(2) $532 million +20% Product sales growth from core products at constant exchange rates(2)(3) +23 ... DUBLIN, August 5 /PRNewswire-FirstCall/ -- - 2009 Guidance Framework Reaffirmed Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2009. Q2 2009 Financial Highlights Q2 2009(1) Product sales $558 million -21% Product sales (excluding ADDERALL XR) $491 million +20% Product sales growth (excluding ADDERALL XR) at ...